Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE

The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG (BAYN)’s Xarelto blood-thinner as a cost- effective way to prevent strokes in people with an irregular heartbeat known as atrial fibrillation.

Deciding whether to start treatment with the drug should be made after the patient and physician have discussed Xarelto’s risks and benefits compared with warfarin, an older treatment, the health-cost agency, known as NICE, said today in an e-mailed statement.

To contact the reporter on this story: Kristen Hallam in London at

To contact the editor responsible for this story: Kristen Hallam at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.